Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last961 to 980 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Newer DA-BLS Training Program vs Current BLS Training Program: deaths from any cause | 1,401 of 1,486 8,090 of 8,641 | 0.7 points -0.7 to 1.9 | 10,127 | NCT02142387 Effects of a New Dispatcher-Assisted Basic Life Support Training Program |
| Districts Which Implement Newer DA-BLS Training Program vs Districts Which Keep Traditional BLS Training Program: Number of Participants With Good Neurological Recovery | 42 of 1,486 316 of 8,641 | -0.8 points -1.7 to 0.2 | 10,127 | NCT02142387 Effects of a New Dispatcher-Assisted Basic Life Support Training Program |
| Newer DA-BLS Training Program vs Current BLS Training Program: serious adverse events | 1,401 of 1,486 8,090 of 8,641 | 0.7 points -0.7 to 1.9 | 10,127 | NCT02142387 Effects of a New Dispatcher-Assisted Basic Life Support Training Program |
| Copayment Intervention Arm vs Usual Care Arm: deaths from any cause | 16 of 6,135 8 of 3,967 | 0.1 points -0.2 to 0.2 | 10,102 | NCT02406677 Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study |
| Tranexamic Acid vs Placebo: Number of Participants With Postpartum Infectious Complications | 162 of 5,080 125 of 5,009 | 0.7 points 0.0 to 1.3 | 10,089 | NCT03364491 Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean |
| Xylitol vs Control: deaths from any cause | 0 of 4,549 2 of 5,520 | -0.0 points -0.1 to 0.1 | 10,069 | NCT02333227 Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi |
| Xylitol vs Control: serious adverse events | 0 of 4,549 2 of 5,520 | -0.0 points -0.1 to 0.1 | 10,069 | NCT02333227 Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi |
| Tranexamic Acid vs Placebo: Number of Participants With Seizure Activity That Was Not Seen Prior to Study Enrollment | 2 of 5,069 0 of 4,996 | 0.0 points -0.0 to 0.1 | 10,065 | NCT03364491 Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean |
| Tranexamic Acid vs Placebo: Number of Participants With a Thromboembolic Event (Venous or Arterial), Ischemic Stroke, or Myocardial Infarction | 12 of 5,069 13 of 4,996 | -0.0 points -0.2 to 0.2 | 10,065 | NCT03364491 Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean |
| Tranexamic Acid vs Placebo: Number of Mothers Who Died or Had Thromboembolic Events (Venous or Arterial), Ischemic Stroke, Myocardial Infarction, New-onset Seizure Activity, or Were Admitted to the Intensive Care Unit for More Than 24 Hours | 35 of 5,069 32 of 4,996 | 0.0 points -0.3 to 0.4 | 10,065 | NCT03364491 Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean |
| Functional Diagnostic Tests vs Anatomic Diagnostic Test: serious adverse events | 161 of 5,007 168 of 4,996 | -0.1 points -0.9 to 0.6 | 10,003 | NCT01174550 PROspective Multicenter Imaging Study for Evaluation of Chest Pain |
| Primary Vaccination Group vs Booster Vaccination Group: serious adverse events | 204 of 6,851 59 of 3,149 | 1.1 points 0.4 to 1.7 | 10,000 | NCT01981967 Post-licensure Safety Study of IMOJEV® in Thailand |
| Brief Clinician Education vs Clinical Decision Support Nudges and Brief Clinician Education: PSA Screening in Older Men | 1,675 of 5,169 1,373 of 4,811 | 3.9 points 2.1 to 5.7 | 9,980 | NCT04289753 Behavioral Economics Applications to Geriatrics Leveraging EHRs R33 Trial |
| Vitamins vs Placebo: Pregnancy Associated Hypertension | 1,457 of 4,993 1,322 of 4,976 | 2.6 points 0.9 to 4.4 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic Group | 60 of 4,993 46 of 4,976 | 0.3 points -0.1 to 0.7 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related Disorders | 13 of 4,993 16 of 4,976 | -0.1 points -0.3 to 0.2 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels | 26 of 4,993 33 of 4,976 | -0.1 points -0.5 to 0.2 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia | 21 of 4,993 31 of 4,976 | -0.2 points -0.5 to 0.1 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Creatinine ≥1.5 mg/dl (133 μmol/Liter) | 9 of 4,993 12 of 4,976 | -0.1 points -0.3 to 0.1 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
| Vitamins vs Placebo: Severe Hypertension | 210 of 4,993 204 of 4,976 | 0.1 points -0.7 to 0.9 | 9,969 | NCT00135707 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=49
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02142387-deaths",
"title": "Newer DA-BLS Training Program vs Current BLS Training Program: deaths from any cause",
"summary": "1401 of 1486 against 8090 of 8641; risk difference 0.7 points, 95% interval -0.7 to 1.9; NCT02142387, Effects of a New Dispatcher-Assisted Basic Life Support Training Program",
"record": "/library/comparisons/NCT02142387-deaths",
"nct_id": "NCT02142387",
"kind": "deaths",
"participants": 10127,
"risk_difference": {
"value": 0.006565229492935032,
"lower": -0.007338595470668225,
"upper": 0.018532179697545677
},
"group_1": "1,401 of 1,486",
"group_2": "8,090 of 8,641",
"difference": "0.7 points",
"interval": "-0.7 to 1.9",
"trial_title": "Effects of a New Dispatcher-Assisted Basic Life Support Training Program"
},
{
"id": "NCT02142387-fd98bd15",
"title": "Districts Which Implement Newer DA-BLS Training Program vs Districts Which Keep Traditional BLS Training Program: Number of Participants With Good Neurological Recovery",
"summary": "42 of 1486 against 316 of 8641; risk difference -0.8 points, 95% interval -1.7 to 0.2; NCT02142387, Effects of a New Dispatcher-Assisted Basic Life Support Training Program",
"record": "/library/comparisons/NCT02142387-fd98bd15",
"nct_id": "NCT02142387",
"kind": "outcome",
"participants": 10127,
"risk_difference": {
"value": -0.008306046029578542,
"lower": -0.016700323930222104,
"upper": 0.002113597167166449
},
"group_1": "42 of 1,486",
"group_2": "316 of 8,641",
"difference": "-0.8 points",
"interval": "-1.7 to 0.2",
"trial_title": "Effects of a New Dispatcher-Assisted Basic Life Support Training Program"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=50",
"request_id": "O_kbJuoAxN7IvlG8"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant